255 related articles for article (PubMed ID: 9102207)
1. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
Zhang QX; Borg A; Wolf DM; Oesterreich S; Fuqua SA
Cancer Res; 1997 Apr; 57(7):1244-9. PubMed ID: 9102207
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
3. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.
Graham ML; Krett NL; Miller LA; Leslie KK; Gordon DF; Wood WM; Wei LL; Horwitz KB
Cancer Res; 1990 Oct; 50(19):6208-17. PubMed ID: 2400987
[TBL] [Abstract][Full Text] [Related]
4. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation.
Duan R; Porter W; Safe S
Endocrinology; 1998 Apr; 139(4):1981-90. PubMed ID: 9528985
[TBL] [Abstract][Full Text] [Related]
6. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Catherino WH; Wolf DM; Jordan VC
Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.
Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS
Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
[TBL] [Abstract][Full Text] [Related]
9. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor.
Hyder SM; Nawaz Z; Chiappetta C; Stancel GM
Cancer Res; 2000 Jun; 60(12):3183-90. PubMed ID: 10866309
[TBL] [Abstract][Full Text] [Related]
10. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Levenson AS; Catherino WH; Jordan VC
J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):261-8. PubMed ID: 9219916
[TBL] [Abstract][Full Text] [Related]
11. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.
Pakdel F; Reese JC; Katzenellenbogen BS
Mol Endocrinol; 1993 Nov; 7(11):1408-17. PubMed ID: 8114756
[TBL] [Abstract][Full Text] [Related]
12. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors.
Ince BA; Schodin DJ; Shapiro DJ; Katzenellenbogen BS
Endocrinology; 1995 Aug; 136(8):3194-9. PubMed ID: 7628351
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells.
Balasenthil S; Barnes CJ; Rayala SK; Kumar R
FEBS Lett; 2004 Jun; 567(2-3):243-7. PubMed ID: 15178330
[TBL] [Abstract][Full Text] [Related]
15. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
16. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
[TBL] [Abstract][Full Text] [Related]
17. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
England GM; Bilimoria MM; Chen Z; Assikis VJ; Muenzner HD; Jordan VC
Int J Oncol; 1998 May; 12(5):981-6. PubMed ID: 9538117
[TBL] [Abstract][Full Text] [Related]
19. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation.
Lazennec G; Alcorn JL; Katzenellenbogen BS
Mol Endocrinol; 1999 Jun; 13(6):969-80. PubMed ID: 10379895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
